Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical tr ...
Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy ...
Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple ...
Shaun Bagai, Chief Executive Officer of RenovoRx, commented, "2025 marked a key year as it was our first full year of RenovoCath commercialization, generating over $1 million in revenue and reflecting ...
Researchers are enrolling patients with small cell lung cancer, neuroendocrine tumors, and melanoma and will evaluate responses based on biomarkers.
AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results